Advent International

Advent International is one of the larger global private equity firms, headquartered in Boston with offices across multiple continents. Within healthcare, the firm concentrates on pharma and therapeutics platforms and diagnostics businesses, deploying capital into established infrastructure rather than discovery-stage science. Advent typically pursues control buyouts of mature operating companies, and its size means individual deals frequently run into the hundreds of millions or billions of dollars. AI is not a stated focus area in the source data.

Check sizes start at $25M and scale far higher, with deployments across North America, Europe, Latin America, and Asia. The firm engages at growth and buyout stages, not earlier. Specific portfolio companies in the healthcare AI category are not listed in the source data.

Advent is not a target for the vast majority of healthcare AI founders. Seed through Series B companies should not approach. The relevant moment to engage is when a company has reached substantial scale, often as part of a strategic process led by an investment bank, or when contemplating a take-private, carve-out, or sponsor-to-sponsor transaction. Founders running smaller rounds will get a faster, better answer from an earlier-stage investor.